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ABSTRACT 
Objective: Cocrystallisation is a promising method in order to increase the solubility and dissolution of poorly water-soluble drugs. The aim of this study 
was to prepare, formulate and evaluate glibenclamide (GCM) cocrystal in direct compress tablet dosage form using saccharin (SAC) as the coformer.  
Methods: GCM cocrystal with various stoichiometric ratios were prepared by the solvent drop grinding method. The co-crystal was characterized 
by a saturated solubility test and dissolution rate test, Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), 
and Powder X-Ray Diffraction (PXRD). The tablet dosage form of GCM was formulated and evaluated compare with the conventional dosage form. 
Results: The solubility and dissolution rate of GCM-SAC cocrystals increased significantly compared with pure GCM, especially for ratio of 1:2. The 
dissolution rate of cocrystal with ratio 1:2 increased by almost 91.9% compared with pure GCM. Based on the FTIR analysis, it showed the shifting 
of characteristic bands of GCM in the spectrum and there was no chemical reaction in GCM cocrystal. In PXRD measurement, the new crystalline 
peak was detected in the crystal habit of cocrystal compared with pure GCM and coformer. The new single melting of GCM-SAC cocrystal also was 
detected in DSC measurement. The tablets of GCM-SAC cocrystal were successfully prepared by direct compression method which rapidly 
disintegrated (1 min) and has higher dissolution compared with its pure form (32.36% greater than glibenclamide after 45 min). 
Conclusion: The tablet dosage form of GCM cocrystal with SAC as coformer was successfully prepared, formulated and improved its solubility and 
dissolution rate. 
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Solubility and dissolution are important factors in the pharmacological 
effect of the drug [1]. Although the level of drug solubility is needed for 
oral absorption, almost 40% of the drug in the market shows low 
solubility in water. Due to the low solubility, the drug is absorbed slowly 
and the levels of the drug in the blood are lower than the required [2, 3]. 
In the biopharmaceutical classification system (BCS), glibenclamide 
(GCM) is included in class II, which means it has high permeability and 
low solubility. GCM is a type 2 antidiabetic drug used for controlling 
glycemia [4]. Glibenclamide has a low solubility of about 4 mg/l [5] and 
its bioavailability is only 40-45%. 
Several studies have been reported about methods improving 
glibenclamide solubility such as fast dissolving tablet (FDT) [6], lipid 
nanocrystal [7], nanoparticles [8, 9], solid dispersion [10, 11], self-
emulsifying drug delivery systems (SEEDS) [12] and liquisolid 
technology [13]. Cocrystal is one method that can increase the solubility 
of the API [14]. Cocrystal can be defined as complex crystal formations 
with stoichiometric multi-component system connected by a synthon 
that in pharmaceutical crystal engineering is called “a non-covalent 
interaction involving hydrogen bonds, in which two distinct components 
are solid under ambient conditions”. The previous study showed that 
cocrystallization method can increase the solubility of GCM compared 
with pure GCM with saccharin and aspartame as the coformer [14, 15].  
In this study, glibenclamide cocrystal was prepared by solvent drop 
grinding using saccharin as the coformer. Saccharin (SAC) is an 
artificial sweetener that commonly used in cocrystallization as the 
coformer. Some several studies reported that using SAC as coformer 
can increase the solubility of carbamazepine, ketoprofen and GCM 
compared with pure drugs [14, 16, 17]. In the last decades, the 
research of cocrystal has grown rapidly, but only a few research 
conduct about the preparation and evaluation of cocrystal in the tablet 
dosage form. Thus, the aim of this study was to prepare, formulate and 
evaluate GCM cocrystal in tablet dosage form using SAC as the 
coformer. The tablet formulation was designed as direct compress 
tablet to minimize manufacturing process impact to GCM cocrystal 
performance. 
MATERIALS AND METHODS 
Materials 
GCM was obtained from Indofarma (Indonesia) with a purity>99% and 
SAC and ethanol pro analysis were obtained from Merck (Germany).  
Preparation of cocrystal 
The cocrystal of GCM-SAC was employed with solvent drop grinding 
method. GCM and SAC were weighted and mixed with different 
molar ratio (1:1, 1:2 and 2:1). The mixture was ground by mortar 
and pestle, during grinding add ethanol as a solvent for 15 min. The 
mixture was dried overnight at ambient temperature.  
Solubility study 
The sample equivalent to 20 mg GCM was placed in vials containing 
water. The vials were agitated using a mechanical agitator at room 
temperature and allowed to stand for equilibrations for 24 and 48 h. The 
samples were filtered through a 0.45 μm membrane filter, diluted with 
distilled water and analyzed spectrophotometrically at 266 nm [15].  
Particulate dissolution study 
Dissolution studies of cocrystals were performed using type 2 
apparatus (paddle). A sample of cocrystals weighed in equal to 50 
mg GCM then put into 900 ml buffer phosphate pH 8 and stirred at 
75 rpm, the temperature was maintained at 37 ± 0.2 °C. The 5 ml of 
samples were filtered through a syringe filter of 0.45 μm pore size 
periodically (at 0, 10, 15, 30, 45, and 60 min) and analyzed by UV 
spectrophotometer at 266 nm [15].  
Characterization of cocrystal 
FTIR analysis  
FTIR analysis was employed to evaluate the interaction between 
drug and coformer. The cocrystal was dispersed homogeneously in 
KBr pellet. The samples were analyzed using an infrared 
spectrophotometer (Shimadzu®) at room temperature in a range of 
wavenumbers from 400-4000 cm-1 [18]. 
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Powder X-ray diffractometer (PXRD) 
The X-ray generator was operated using Phillip PW 1835 at 40 kV and 
40 mA using CuKα radiation. The scans were performed between 3  oand 
40 ᵒ with a scanning rate of 4 ᵒ/min at room temperature [14]. 
Differential scanning calorimetry (DSC)  
DSC analysis was performed using Linseis DSC PT1000. 
Approximately 5 mg of the powder sample was placed in an 
aluminum pan and heated at a rate of 10 °C/min, from 0 to 300 °C 
temperature range, under nitrogen stream [19, 20]. 
Formulation of cocrystal tablet 
An accurately weighed quantity of cocrystal equivalent to drug dose 
(5 mg) and all other ingredients was mixed. The mixture was 
directly compressed into tablets. Round concave tablets of 100 mg 
mass were obtained [21]. Table 1 outlines the composition of tablet 
formulations.
 
Table 1: Formulation of cocrystal tablet 
Ingredients Amount (mg/tablet) 
F1 (1:1) F2 (1:2) F3 (2:1) 
Cocrystals 5 5 5 
Mg stearate  0.5  0.5  0.5  
Ludipress  Add up to 100 
 
Evaluation of cocrystal powder (pre-compression parameters) 
The mixture of drug and excipient were evaluated for tapped 
density, bulk density, and flow properties and compressibility 
parameters. Flow properties of powder were determined by the 
angle of repose and compressibility by Carr's index [22, 23].  
Evaluation of cocrystal tablet (post-compression parameters) 
The thickness and weight variation  
Twenty tablets were randomly taken from each formulation and 
thickness was measured using Vernier caliper. The results are 
expressed as mean±standard deviation (SD). The average weight of 
twenty tablets was determined using an electronic balance and 
tablet were weighed individually and compared to average weight.  
Hardness test  
Ten tablets were randomly selected from each batch and hardness of 
tablets was determined by using hardness tester. The mean values 
and standard deviation for each batch were calculated [24].  
Friability test  
The friability of tablets was measured using friability tester. Twenty 
tablets were placed in plastic friability tester attached to motor 
revolving at a speed of 25 rpm for 4 min. The tablets were then 
deducted, reweighed, and percent weight loss was calculated using 
the formula,  
% friability = ((initial weight–final weight)/initial weight)×100 [23]. 
In vitro disintegration time  
Determination in vitro disintegration time (DT) using distilled water 
at 37±2 °C. The time when the tablets were disintegrated completely 
without any residue remaining in the apparatus was recorded as 
mean±SD [24].  
In vitro dissolution study 
Dissolution test of tablet glibenclamide cocrystal was performed using 
type 2 apparatus (paddle type). A sample tablet put into 900 ml buffer 
phosphate pH 8 and stirred at 100 rpm, temperature 37 ± 0.2 °C. 
Sampling (5 ml) until 60 min at predetermined interval times (5, 10, 
15, 30, 45, 60 min) and 5 ml of fresh medium was added after each 
sampling. The sample was analyzed using a UV Spectrophotometer to 
quantify the amount of dissolved GCM concentration [25]. 
RESULTS AND DISCUSSION 
Preparation of cocrystal 
The preparation of the GCM and SAC cocrystal was carried out by 
solvent drop grinding (SDG). The SDG method is reliable in the 
discovery of new cocrystals because the presence of a solvent can 
improve the rate of cocrystal formation and is suitable for cocrystal 
constituents with the equimolar ratio [26]. By grinding with minimal 
addition the solvent, the SDG can control over the polymorphic 
outcome of cocrystal [27]. In this experiment, saccharin was chosen 
as the coformer because of its stability, polarity, and ability to form a 
heterosynthon in cocrystal [2]. The purpose of using this method is 
to demonstrate an 'environmentally friendly' method of generating 
GCM-SAC cocrystals [28]. 
Solubility test 
Based on fig. 1, the solubility of cocrystal (1:2) was higher than the 
solubility of its pure form and other cocrystals (1:1 and 2:1) for 24 
and 48 h. This indicated that the molecular interaction between GCM 
with SAC has successfully occured and can form a cocrystals state 
[25]. The interaction between hydrogen atoms of the amide groups 
from GCM and oxygen atoms of sulfonyl from SAC might have 
formed the hydrogen bonds [15]. Saccharin has a strong hydrogen 
bond acceptor (C=O) and strong donors (N–H) to form a robust 
homodimer synthon in the crystal structure with GCM [28]. In 
addition, the higher hydrophilicity of coformer tend to ease the 






Fig. 1: The result of the solubility study of the cocrystal (a) 24 h 
(b) 48 h (All the values were calculated as mean±SD) 
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Particulate dissolution test 
Based on fig. 2, the dissolution rate of cocrystal was higher than its 
pure form. In this study, pure GCM dissolved 32.30±0.21% in 60 min. 
However, the cocrystal with ratio 1:1, 1:2, and 2:1 dissolved 
45.11±2.39%, 61.99±2.15%, and 41.73±2.39% in 60 min respectively. 
It is assumed that the GCM cocrystal has a weaker crystalline structure 
that can increase the dissolution rate of GCM. Moreover, the changed 
crystallinity pattern, crystal habit, size and shape of cocrystal can be 
attributed to increasing dissolution of GCM [25]. Increasing the 
dissolution rate is related to the diffusion constant, the function of the 
surface area, boundary-layer thickness, and solubility [26]. 
   
 
Fig. 2: In vitro dissolution study of the cocrystal (All the values were calculated as mean±SD) 
 
Characterization of co-crystal  
FTIR analysis 
 
Fig. 3: Overlay Infrared spectrum of pure glibenclamide (green line), saccharin (black line), and glibenclamide-saccharin cocrystal (red line) 
 
The weakened C=O peak could confirm hydrogen bond formation 
between GCM and SAC (table 2). Interaction of GCM and SAC was 
predicted between amide groups of glibenclamide and sulfonyl 
group of saccharin [14]. In FTIR analysis, there were no new peaks 
observed, indicating that no chemical reaction occurred during 
cocrystal preparation.  
 
Table 2: The characteristic peak of infrared 
Functional group Wavenumber (cm-1) 
Glibenclamide Saccharin  Cocrystal 




O-H stretch 3116.97 3093.82 3093.82 




C=O stretch 1716.65 1724.36 1728.22 
C=C stretch 1616.35  1616.35 
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Powder X-ray diffraction 
PXRD was performed to verify the formation of the cocrystal of GCM. 
All crystal forms of a compound show the characteristic on 
diffractogram pattern of drug [26]. The overlay of the diffractogram 
showed peaks and intensity at an angle of 2θ of pure GCM is 10.7 °, 
12.3 °, 19.5 °, 19.8 °, 20.9 °, 22.1 ° and intensity at an angle of 2θ of 
SAC is 9.01 °, 15.2 °, 19 °, dan 24 °. A different powder X-ray pattern 
for the GCM-SAC cocrystals from those of the constituent GCM and 
saccharin confirms the formation of a new cocrystal phase [28]. 
Differential scanning calorimetry (DSC)  
DSC studies are performed to observe the solid-state interaction of 
two compounds or more by giving heat energy to the co-crystals to 
evaluate thermodynamic changes (endothermic or exothermic 
peaks) [26]. The thermogram fig. 5 showed that the melting point of 
cocrystal (144.5-166.9 °C) was lower than pure GCM (169.6-185.1 
°C). The change in thermal properties (melting point) indicated as 
evidence for the formation of cocrystal. A decrease in the melting 
point of the cocrystal directly correlates with increased solubility of 
GCM in the cocrystal system [26]. 
 
 
Fig. 4: Diffractogram of glibenclamide, saccharin, and cocrystal 
 
 
Fig. 5: Thermogram of glibenclamide (a), Saccharin (b), and Cocrystal (c) 
 
Table 3: Evaluation of pre-compression 
Parameters F1 (1:1) F2 (1:2) F3 (2:1) 
Angle of repose ( °) 15.94 15.94 15.94 
Bulk density (g/ml) 0.56 0.56 0.56 
Tapp density (g/ml) 0.64 0.64 0.64 
Index Carr (%) 11.27 11.27 11.27 
 
Evaluation pre-compression and post-compression 
The bulk density of all the formulations was found to 0.56 g/ml, 
tapped density was 0.64 g/ml, angle of repose 15.94 °, and index 
carr was 11.27 % indicating good flow property of tablet granules 
and tablet of cocrystal could be compressed directly. Results of post-
compression such as weight variation, diameter, thickness, 
hardness, friability, and disintegration time are reported in table 4. 
These evaluations indicated that the stoichiometry ratio of cocrystal 
was not affected mechanical properties of GCM. 
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Table 4: Evaluation of post-compression (All the values were calculated as mean±SD) 
Formulation Weight variation (mg) Diameter (mm) Thickness (mm) Hardness (N) Friability (%) Disintegration time (min) 
F1 (1:1) 102.80±1.11 0.62±0.005 0.31±0.005 37.50±2.56 0.96±0.01 1.20±0.05 
F2 (1:2) 103.15±0.93 0.61±0.006 0.31±0.005 37.75±2.49 0.96±0.02 1.30±0.06 
F3 (2:1) 102.95±1.00 0.62±0.005 0.31±0.006 38.00±2.45 0.97±0.01 1.20±0.06 
 
 
Fig. 6: In vitro drug release study of glibenclamide cocrystal tablet dosage form (All the values were calculated as mean±SD) 
 
In vitro dissolution study of tablet cocrystal 
The drug release of all cocrystal formulations were more than 80% 
at 60 min. The tablets of 1:2 cocrystal was the highest drug release 
percentage among other tablets. However, cocrystallization 
glibenclamide was still potential because the tablet was made by 
direct compression method. Drug release percentage of pure 
glibenclamide tablet after 45 min, cocrystal 1:1, 1:2, 2:1 were 65.32 
%; 94.06 %; 97.68 %; and 88.65 % respectively. 
CONCLUSION 
The solubility and dissolution rate of GCM-SAC cocrystals increased 
significantly compared with pure GCM, especially for ratio of 1:2. 
The dissolution rate of cocrystal with ratio 1:2 increased by almost 
91.9% compared with pure GCM. Based on the FTIR analysis, it 
showed the shifting of characteristic bands of GCM in the spectrum 
and there was no chemical reaction in GCM cocrystal. In PXRD 
measurement, the new crystalline peak was detected in the crystal 
habit of cocrystal compared with pure GCM and coformer. The new 
single melting of GCM-SAC cocrystal also was detected in DSC 
measurement. The tablets of GCM-SAC cocrystal were successfully 
prepared by direct compression method which rapidly disintegrated 
(1 min) and has higher dissolution compared with its pure form 
(32.36% greater than glibenclamide after 45 min). 
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